KRT1

Overview

KRT1 encodes keratin 1, a type II intermediate filament protein and one half of the most abundant keratin pair in the outer layers of human skin. Like all type II keratins, KRT1 cannot form filaments on its own. It must heterodimerize with a type I partner, in this case keratin 10 (KRT10), and the resulting KRT1-KRT10 pair is switched on as basal keratinocytes commit to terminal differentiation and move upward into the spinous and granular layers of the epidermis.

The KRT1-KRT10 filament network is a major source of the skin’s mechanical resilience. These intermediate filaments span the keratinocyte cytoplasm and anchor to desmosomes, the cell-cell junctions that stitch neighboring keratinocytes together, forming a continuous, shock-absorbing scaffold across the tissue. This is why disrupting KRT1 has such a dramatic clinical effect: when the filament network cannot assemble properly, individual keratinocytes become fragile and rupture under ordinary mechanical stress.

That fragility defines epidermolytic hyperkeratosis, a dominantly inherited disorder caused by mutations in the rod domain of KRT1 or KRT10. Affected infants present with widespread blistering at birth, which evolves over time into thickened, warty hyperkeratosis as the skin’s response to chronic mechanical injury. A milder, more localized disease, non-epidermolytic palmoplantar keratoderma, results when mutations instead fall in a different part of KRT1, the V1 end domain, sparing the load-bearing rod domain and confining the phenotype largely to the palms and soles.

More recent research has shown that KRT1 is not purely a structural protein. It participates in an interleukin-18-dependent inflammatory signaling network in skin and has been identified as a cell-surface receptor for coagulation-related kininogen on endothelial cells, and common KRT1 polymorphisms have been associated with systemic lupus erythematosus and systemic sclerosis susceptibility, connecting a well-characterized structural gene to broader questions in autoimmune disease genetics.

Deep Dive

Filament Assembly and Its Fragile Points

Intermediate filament assembly follows a defined hierarchy, and understanding where that hierarchy can fail explains the genetics of keratin disease.

• Dimer to filament progression: KRT1 and KRT10 monomers first form a coiled-coil heterodimer through their central rod domains, which then associate into tetramers and ultimately assemble into mature intermediate filaments roughly 10 nanometers in diameter.
• Helix boundary motifs as weak points: The short helix initiation and helix termination sequences at each end of the rod domain are especially sensitive to disruption. Most epidermolytic hyperkeratosis-causing mutations cluster in these boundary motifs because they are essential for filaments to elongate and pack correctly, so even a single substituted amino acid there can propagate a defect through the entire network.
• Dominant-negative behavior: Because a mutant KRT1 or KRT10 monomer can still heterodimerize with an otherwise normal partner, a single mutant allele poisons filament assembly throughout the cell, explaining why epidermolytic hyperkeratosis is inherited as an autosomal dominant trait.

Domain-Specific Genotype-Phenotype Correlation

Where a KRT1 mutation falls within the protein strongly predicts the resulting clinical picture, a relatively clean example of genotype-phenotype correlation in dermatology.

• Rod domain mutations: Disrupt the load-bearing coiled-coil structure directly, producing the generalized blistering and cytolysis characteristic of classic epidermolytic hyperkeratosis.
• V1 end domain mutations: Fall outside the rod domain entirely, in a glycine-rich tail region, and instead produce a comparatively mild, non-blistering keratoderma restricted to the palms and soles, tissues subjected to the highest routine mechanical stress.
• Clinical implication: Genetic testing that localizes a KRT1 variant to a specific domain can help anticipate disease severity and guide counseling before the full clinical picture has necessarily emerged, particularly in a newborn presenting with blistering of uncertain cause.

Beyond Structure: Inflammatory and Vascular Roles

Work over the past two decades has broadened KRT1’s functional profile past pure cytoskeletal support.

• Interleukin-18 network: KRT1 participates in regulating IL-18 processing and release in skin, positioning a structural keratin within the epidermis’s innate immune signaling apparatus rather than treating barrier integrity and inflammation as fully separate systems.
• Endothelial kininogen binding: Cytokeratin 1 on the surface of endothelial cells binds high-molecular-weight kininogen, placing it alongside other receptors in the contact activation pathway that links surface-exposed proteins to coagulation and inflammation cascades.
• Autoimmune disease associations: Common coding polymorphisms in KRT1, including the rs14024 variant, have shown association with systemic lupus erythematosus and systemic sclerosis susceptibility in case-control studies, though the mechanistic link between these common variants and autoimmune pathophysiology remains an active research question rather than an established causal pathway.

Diagnostic and Management Considerations

Because KRT1-related disease spans a spectrum from severe congenital blistering to a subtle, adult-onset palmoplantar keratoderma, diagnosis and management vary considerably by presentation.

• Genetic confirmation: Targeted sequencing of KRT1 and KRT10 has largely replaced electron microscopy as the diagnostic standard, though the characteristic clumped tonofilament and perinuclear vacuolization findings on skin biopsy remain a useful adjunct when genetic results are ambiguous.
• Supportive skin care: Emollients, keratolytics, and infection precautions form the backbone of management for both epidermolytic hyperkeratosis and palmoplantar keratoderma, since no therapy yet directly corrects the underlying filament assembly defect.
• Prognostic counseling: Because epidermolytic hyperkeratosis severity often improves somewhat from infancy into adulthood despite an unchanged genetic lesion, counseling families at the time of neonatal diagnosis benefits from acknowledging this expected trajectory rather than anchoring solely on the severity of the initial presentation.